Y-mAbs Therapeutics to Current at forty first Annual J.P. Morgan Healthcare Convention
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Firm” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical firm centered on the event and commercialization of novel, antibody-based therapeutic merchandise for the therapy of most cancers, as we speak introduced that its founder, President and Interim Chief Government Officer, Thomas Gad, will present an outline and replace on the Firm’s enterprise on the digital forty first Annual J.P. Morgan Healthcare Convention. The presentation will happen on Wednesday, January 11, 2023, at 5:15 PM Japanese Normal Time. The presentation will be accessed by way of a reside audio webcast.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical firm centered on the event and commercialization of novel, antibody-based therapeutic most cancers merchandise. Along with typical antibodies, the Firm’s applied sciences embody bispecific antibodies generated utilizing the Y-BiClone platform and the SADA platform. The Firm’s broad and superior product pipeline consists of one FDA-approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that specific GD2, and one product candidate on the registration-stage, OMBLASTYS® (omburtamab), which targets tumors that specific B7-H3.
Ahead-Wanting Statements
Statements on this press launch about future expectations, plans and prospects, in addition to every other statements concerning issues that aren’t historic info, could represent “forward-looking statements” inside the which means of The Non-public Securities Litigation Reform Act of 1995. Such statements embody, however should not restricted to, statements concerning the potential of the Firm’s merchandise and product candidates, together with DANYELZA®, the Y-BiClone know-how and the SADA know-how, together with bi-specific and SADA constructs, and the potential advantages thereof; the Firm’s enterprise plans and prospects; collaborations or strategic partnerships and the potential advantages thereof; the Firm’s enterprise mannequin and growth, commercialization and product distribution plans; present and future scientific and pre-clinical research and our analysis and growth applications; potential for DANYELZA territory and label growth, and development of the Y-BiClone know-how and SADA know-how; and different statements that aren’t historic info. Phrases akin to ‘‘anticipate,’’ ‘‘consider,’’ “ponder,” ‘‘proceed,’’ ‘‘might,’’ ‘‘estimate,’’ ‘‘count on,’’ “hope,” ‘‘intend,’’ ‘‘could,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘challenge,’’ ‘‘ought to,’’ ‘‘goal,’’ “will”, ‘‘would’’ “purpose,” “goal,” and related expressions are meant to establish forward-looking statements, though not all forward-looking statements include these figuring out phrases. Our product candidates and associated applied sciences are novel approaches to most cancers therapy that current important challenges. Precise outcomes could differ materially from these indicated by such forward-looking statements because of numerous components, together with however not restricted to: dangers related to our monetary situation and wish for added capital; dangers related to our growth work; price and success of our product growth actions and scientific trials; the dangers of delay within the timing of our regulatory submissions or failure to obtain approval of our drug candidates; the dangers associated to commercializing any authorised pharmaceutical product, together with the speed and diploma of market acceptance of our product candidates; growth of our gross sales and advertising capabilities and dangers related to failure to acquire ample reimbursement for our merchandise; the dangers associated to our dependence on third events, together with for conduct of scientific testing and product manufacture; our incapacity to enter into partnerships; the dangers associated to authorities regulation; dangers associated to market approval; dangers related to safety of our mental property rights; dangers associated to worker issues and managing progress; dangers associated to our frequent inventory; dangers related to the COVID-19 pandemic; dangers related to the battle between Russia and Ukraine and sanctions associated thereto, macroeconomic circumstances, together with inflation and unsure world credit score and capital markets; and different dangers and uncertainties affecting the Firm together with these described within the “Threat Components” part included in our Annual Report on Type 10-Ok for the 12 months ended December 31, 2021 filed with the Securities and Change Fee (the “SEC”) and in our different SEC filings, together with our Quarterly Stories on Type 10-Q for the quarters ending March 31, 2022, June 30, 2022, and September 30, 2022 in addition to in our different SEC filings. Any forward-looking statements contained on this press launch communicate solely as of the date hereof, and the Firm undertakes no obligation to replace any forward-looking assertion, whether or not because of new data, future occasions or in any other case besides as required by legislation.
DANYELZA®, OMBLASTYS® and Y-mAbs® are registered logos of Y-mAbs Therapeutics, Inc.
Contact:
Y-mAbs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York, NY 10169
USA
+1 646 885 8505
E-mail: [email protected]
